Skin Models

Intradermal device testingA collaboration study with Pharma LatchReplacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1, Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM thatRead more

Local toxicity & Formulation safetyA collaboration study with argenxHypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2, Judith Baumeister1 1argenx, 2Genoskin Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin enables multi-parametric local tolerance assessment after subcutaneous injection.Read more

Explore how NativeSkin® supports ethical, human-relevant, and translational research in UV testing, phototoxicity assessment, and photobiology.

Download this application note and discover 3 case studies. Refine formulations or assess local tolerance in human skin before clinical trials.

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm theRead more

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.